Navigation Links
eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
Date:5/20/2008

PHILADELPHIA, May 20 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that Dr. Michael J. McKelvey, the Company's President and Chief Executive Officer, and Richard Baron, the Company's Chief Financial Officer, are scheduled to present at the FBR 12th Annual Spring Investor Conference at 9:00 a.m. Eastern on May 28, 2008 at the Grand Hyatt Hotel in New York, New York.

Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com or (Due to the length of the URL please copy and paste into your browser.) http://guest.cvent.com/EVENTS/Info/Custom.aspx?cid=20&e=53124f2c-1b1a-40ac- bb48-63c7d3febed2. The webcast will be available via replay for 90 days.

About eResearchTechnology:

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Forward-looking Statements:

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Report on Form 10-K and 10Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
7. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
8. eResearchTechnology Reports First Quarter 2008 Results
9. eResearchTechnology Announces Resignation of its CFO
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. , an ... technology has been recognized As “ Best in Semantic Web Technology - USA ... Corporate America, it’s our priority to showcase prominent professionals who are excelling in ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... series of potential targets (epitopes) specific to misfolded, propagating strains of Amyloid beta ... specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from the first misfolded ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... products to aid in the rapid development and ongoing quality control of molecular ... Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ...
Breaking Biology Technology:
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
Breaking Biology News(10 mins):